Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
常山药业
300255
Shenzhen Stock Exchange
Company Profile
Changshan Pharma is one of the few leading enterprises in China that has a complete heparin industrial chain and can conduct the research, production and sales of heparin API as well as injections. The main products of Changshan Pharma include Heparin Sodium API, Enoxaparin sodium API, Dalteparin Sodium API, Low Molecular Weight Heparin Calcium API, Heparin Sodium Injection, Dalteparin Sodium Injection and Low Molecular Weight Heparin Calcium Injection. Among them, Low Molecular Weight Heparin Calcium Injection produced by Changshan Pharma has a much higher standard than that set by the national standard, and its effect is good. The product is widely recognized by the market and is the core product of Changshan Pharma. Many products have got the EDQM CEP certification, Japanese PMDA certification, German GMP certification, American FDA certification and so on. At present, the products have been sold to many countries such as the American, Germany, Italy, South Korea, Russia, India, Iran, Japan and many other countries. In the future, Changshan Pharma will carry out the strategy with the heparin series as core and the anti-diabetes drugs as well as oncology drugs as two wings, and actively explore overseas markets and promote the export of preparations. The company will strengthen the research and production of silaenafil and hyaluronic acid, develop diversification and enter the new field of medical services. At the same time, the company will speed up the mergers and acquisitions of pharmacy and medical treatment, explore the new growth point the company development, continue to expand the scale of enterprises, enhance core competitiveness and ability to resist risks, and make the company bigger and stronger as soon as possible. The company will improve its R & D capability, enlarge is business scope, promote its development as well as efficiency.
Full description
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded on September 28th, 2000. Since its inception, the company has always been committed to the research, production and sales of heparin series products. After years of development, Changshan Pharma is one of the few leading enterprises in China that has a complete heparin industrial chain and can conduct the research, production and sales of heparin API as well as injections. As a key high-tech enterprise of China Torch Program, the company has won such honors and titles as “Innovative Enterprise of Hebei Province”, “Hebei Excellent Private Technology Enterprise”, “Hebei Excellent Export Enterprise”, etc. The company has established the National-local Joint Engineering Laboratory of polysaccharide production technology, and the research team of polysaccharide and protein polypeptide has been awarded the title of Innovation and Entrepreneurship Team of “giant plan” in Hebei province. The main products of Changshan Pharma include Heparin Sodium API, Enoxaparin sodium API, Dalteparin Sodium API, Low Molecular Weight Heparin Calcium API, Heparin Sodium Injection, Dalteparin Sodium Injection and Low Molecular Weight Heparin Calcium Injection. Among them, Low Molecular Weight Heparin Calcium Injection produced by Changshan Pharma possess an obviously higher quality standard than the national quality standard, and its effect is good. This product has been widely recognized by the market and is the core product of Changshan Pharma. Many products of Changshan Pharma have got the EDQM CEP certification, Japanese PMDA certification, German GMP certification, American FDA certification etc. At present, the products have been sold to many countries such as the American, Germany, Italy, South Korea, Russia, India, Iran, Japan and many other countries. In the future, Changshan Pharma will implement the strategy with the heparin series as core and the anti-diabetes drugs as well as oncology drugs as two wings, actively explore overseas markets and promote the export of preparations. The company will strengthen the research and production of silaenafil and hyaluronic acid, develop diversification and enter the new field of medical services. At the same time, the company will speed up the mergers and acquisitions of pharmacy and medical treatment, explore the new growth point of the company development, continue to expand the scale of enterprises, enhance core competitiveness and ability to resist risks, and make the company bigger and stronger as soon as possible. The company will improve the R & D capability, enlarge the business scope, promote the development and improve the efficiency.